Skip to content
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Natural Alternatives International Inc. NAII

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$142.5M
▲ 9.7% YoY
$-20.7M
$-12.6M
▼ 644.3% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Natural Alternatives International, Inc. provides private-label contract manufacturing services, as its primary business activity, to companies that market and distribute vitamins, minerals, herbal and other nutritional supplements, as well as other health care products, to consumers within and outside the United States. It also owns a patent estate related to the raw material ingredient beta-alanine, commercialized primarily through direct sale of the raw material and supply agreements with third parties under its CarnoSyn, SR CarnoSyn and TriBsyn trademarks. Its operations comprise two reportable segments: private-label contract manufacturing, and royalty, licensing and raw material sales. For the fiscal year ended June 30, 2025, private-label contract manufacturing generated $121,779 thousand in net sales, representing 94% of total net sales, compared to $105,358 thousand and 93% in fiscal year 2024. As of June 30, 2025, it employed 215 full-time employees in the United States, three of whom were executive officers of the Company. Originally founded in 1980, Natural Alternatives International, Inc. reorganized as a Delaware corporation in 1989.

Written from the business description in NATURAL ALTERNATIVES INTERNATIONAL INC's annual report to the U.S. Securities and Exchange Commission, filed 23 September 2025. Every sentence was checked against that document before publication.

Growth

USD 142.5M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 142.5 · Net income -20.7
100M200M-10M-20M
201020132016201920222025
Compound annual growth
−2.6%
−4.4%
+2.2%
+6.4%
−61.0%
−53.5%
−18.0%
−9.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −4.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−15 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -13.2% · Net -14.5%
5%10%-5%-10%
201020172025
ROE
FY2025 · ROE -35.0%
5%10%15%-10%-20%-30%
201020172025
Three returns, three denominators.

Each USD of equity lost 35 cents this year.

Cash & shareholders

USD 89,000.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -12.6
10M20M-10M-20M
201020172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 0.1
2M4M
201020122014201620182020202220242025

USD 89,000.00 in buybacks went back to shareholders in a year without profit.

Total assetsUSD 126.4M
EquityUSD 50.0M
CashUSD 7.4M
Current ratio1.73×

Equity funds 40% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
NAII, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.10.10.10.20.20.20.10.10.10.10.10.10.10.10.10.1
Operating income $B−0.0−0.0−0.00.00.00.0−0.00.00.00.00.00.00.00.00.00.0
EBITDA $B−0.0−0.0−0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Income tax $B0.00.0−0.00.00.00.0−0.00.00.00.00.00.00.00.00.0−0.0
Net income $B−0.0−0.0−0.00.00.00.0−0.00.00.00.00.00.00.00.00.00.0
Free cash flow $B−0.00.0−0.0−0.0−0.00.0−0.00.0−0.00.0−0.00.00.00.0−0.00.0
EPS, diluted $−3.43−2.28−1.230.431.741.69−0.250.920.731.091.440.490.290.230.590.71
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−35.0−18.0−8.42.812.714.2−2.29.17.812.619.67.84.83.911.014.3
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 80 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image